Back to top
more

Emmaus Life Sciences (EMMA)

(Delayed Data from OTC)

$0.11 USD

0.11
41

0.00 (0.00%)

Updated Apr 16, 2024 12:31 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for December 13th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Acceleron Discontinues Mid-Stage Muscular Dystrophy Study

Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.

Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

FDA Grants Orphan Drug Status to Acceleron's PAH Candidate

The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.

Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why

Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.

Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.